Objective: To investigate whether change in concentrations over time of aggrecanase generated ARGSaggrecan in synovial fluid (SF ARGS) associates with progression of radiographic knee osteoarthritis (OA) and patient-reported outcome in subjects with previous meniscectomy. Methods: We studied 141 subjects at two time points after meniscectomy. Time point A was on average 18 years after meniscectomy, time point B was on average 7.5 years later; 74 subjects had SF available from both examinations. We measured SF ARGS by an electrochemiluminescence immunoassay, graded radiographic features of tibiofemoral or patellofemoral OA according to the Osteoarthritis Research Society International (OARSI) atlas, and scored patient-reported outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Using logistic regression (adjusted for age, gender, body mass index, time between examinations, and SF ARGS at first examination) we assessed associations between change in SF ARGS between first and second examinations and progression of radiographic OA and KOOS. Results: In subjects with decreasing SF ARGS between examinations, the likelihood of loss of joint space and worsening of KOOS pain between examinations was increased 6-and 4-fold respectively compared to those increasing in SF ARGS (odds ratio (OR) 5.72; 95% confidence interval (CI) 1.53e21.4 and 3.66; 1.01e13.2, respectively). No significant associations were seen between decreasing SF ARGS and progression of osteophytes (OR 0.88; 0.28e2.78), or for patient-reported outcomes other than KOOS pain. Conclusion: Having decreasing levels of SF ARGS over time was associated with an increased risk of loss of joint space and pain worsening, but showed no association with other patient-reported outcomes or osteophyte progression.
Introduction
Osteoarthritis (OA) is distinguished by loss of cartilage, alterations of subchondral bone, formation of osteophytes, and is associated with pain and function limitations 1 . Much effort has been put into the development of OA biomarkers in search of tools to enable earlier diagnosis and prognosis 2, 3 .
Aggrecan is a major constituent in articular cartilage and is of crucial importance for load distribution and shock-absorption. Two aggrecanolytic enzymes with increased expression and activity in pathology are the aggrecanases a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS-4) and ADAMTS-5 (also known as aggrecanase 1 and 2, respectively) 4 . They both cleave aggrecan at the Glu 392 -Ala 393 bond (amino acid numbering based on the accession number [Swiss-Prot: P16112] for human aggrecan) in the interglobular domain resulting in the release of aggrecan 393 ARGS-neoepitope fragments carrying the majority of the fixed negative charges of aggrecan.
Joint injury predisposes individuals to develop OA 5e8 . We have shown that the release from cartilage into synovial fluid (SF) of aggrecanase generated ARGS-aggrecan is highly elevated after knee trauma, and then with time gradually reverts toward normal levels 9, 10 . We have further reported that 18 years after a meniscus injury treated by meniscectomy, SF levels of ARGS-aggrecan are no different from uninjured and un-operated individuals, but higher concentrations within these relatively normal levels were associated with less progression of radiographic knee OA (ROA) over the next 4e10 years 11 . Our proposed hypothesis for this association was an effect of higher levels of aggrecan synthesis in combination with aggrecanase activity, leading to both an increased release of ARGS into SF and a net beneficial incorporation into cartilage 11 .
The primary aim of the present study was therefore to investigate if changes in SF levels of ARGS-aggrecan over 4e10 years were associated with progression of ROA. We hypothesised that individuals with decreasing levels of SF ARGS over time would have an increased risk of ROA progression. A secondary aim was to investigate whether SF ARGS levels, or change in those levels over time, were associated with changes in patient-reported outcomes, using the Knee Injury and Osteoarthritis Outcome Score (KOOS) 12, 13 .
Materials and methods

Materials
Chemicals were as described 14 . Human recombinant ADAMTS-4 15 and monoclonal antibody (MAb) OA-1 were from Glax-oSmithKline (Collegeville, PA, USA). MAb AHP0022 against human aggrecan was from Invitrogen (Carlsbad, CA, USA). High bind MA600 96-well microtitre plates (no. L11XB-1), streptavidin with Sulfo-Tag (streptavidin tagged with the reporter molecule ruthenium (II) tris-bipyridyl, no. R32AD), 4Â Read Buffer T with surfactant (no. R92TC) and the Sector Imager 6000 with software Discovery Workbench 2006 MSD_3_0_18 were from Meso Scale Discovery (MSD, Gaithersburg, MD, USA).
Subjects
The study was approved by the ethics committee of the Faculty of Medicine at Lund University; informed consent was obtained from all participants. Subjects were from a cohort of 317 patients, retrospectively identified to have undergone isolated meniscectomy at Lund University Hospital in 1973, 1978 or 1983e1985 16 . The first examinations (A) were performed 1994, 1995 and 2000, respectively, and the second examination (B) in 2004. The mean (range) time from meniscectomy to examination A was 18 (15e22) years and the time between examinations A and B was 7.5 (4e10) years ( Fig. 1 ). As described 16 , reasons for exclusion were previous knee surgery, meniscectomy in both knee compartments, osteochondritis dissecans, fracture in or adjacent to the knee, septic arthritis, osteonecrosis, any ligament injury, or radiographic signs of knee OA at time of surgery. Out of 859 identified subjects, 456 fulfilled criteria and were invited to participate at examination A, 329 responded and 317 had radiographs taken. Here we further excluded subjects with end-stage OA (defined below) of the index knee at examination A. Out of the 317 available subjects, 141 had complete radiographic and demographic data, and SF at examination A; these were included as the Study cohort n ¼ 141 ( Fig. 2 ) with characteristics as described 11 . Of the included 141 subjects with SF at examination A, a subset of 74 had SF available also from examination B in average 7.5 years later and were studied as Subset n ¼ 74 for investigation of longitudinal change in SF levels of ARGSaggrecan ( Fig. 2 ). Characteristics of Subset n ¼ 74 is presented in Table I . Based on the previously noted association between SF ARGS at examination A and loss of joint space between examination A and examination B 11 , the subjects in Subset n ¼ 74 were also stratified for increasing or decreasing SF ARGS levels from examination A to examination B (Table I) .
Radiographic examination
Radiographs of the tibiofemoral (TF) and patellofemoral (PF) joints were obtained as described 11 . Joint space narrowing (JSN) and osteophytes in the TF and PF joints were graded on a four point scale (0e3, where 0 ¼ no evidence of JSN or osteophytes) according to the 1995 atlas of Osteoarthritis Research Society International (OARSI) 17, 18 , as described 11 . We considered progression of JSN, osteophytes, or their sum (progression of ROA) to have occurred with an increase from examination A to examination B of the respective scores by one or more in any of the TF compartments or the PF compartment. This includes both incident JSN and osteophytes at examination B and worsening of already existing changes 11 .
ROA
A knee was defined as having ROA with any of the following: 
End-stage OA
A knee was considered to have end-stage ROA either (1) with JSN grade 3 in any of the TF compartments or in the PF compartment, or (2) when a subject had undergone subsequent tibial osteotomy or arthroplasty for OA.
Self-reported patient-relevant outcomes by KOOS
For assessment of patient-relevant outcomes we used the selfadministered questionnaire KOOS 12, 13 . The KOOS questionnaire covers the five patient-relevant dimensions pain, other symptoms, function of daily living, function in sports and recreation, and kneerelated quality of life, with scores ranging from 0 (worst) to 100 (best) 12, 13 , and was scored according to the instructions on the KOOS home page 19 . A decline between examinations by 10 units or more was used as cut-off for a clinically relevant progression in all subscales 20 . Our primary outcome for patient-relevant outcomes was progression in KOOS pain by 10 units or more, but we also studied progression in the other four KOOS dimensions.
Measurement of ARGS-aggrecan by aggrecan capture OA-1 ARGS electrochemiluminescence (ELCL) assay SF samples were aspirated (without lavage) from the index knee joint of patients with previous meniscectomy. The fluids were at the time of aspiration centrifuged at 3,000 g, with the supernatants stored at À80 C. SF concentrations of aggrecan fragments containing the ARGS neoepitope were measured using an ELCL technology 21 on the MSD platform recently developed in our laboratory 11 . It is an assay that uses an anti-human aggrecan capture antibody (AHP0022, Invitrogen), reactive against the globular domains 1 and 2 (G1 and G2) of human aggrecan, in combination with the MAb OA-1 22 , specific for the ARGSneoepitope within the interglobular domain of aggrecan. The assay and its evaluation has been described in detail 11 . Briefly, 25 ml aliquots of SF samples were, after deglycosylation, analysed for ARGS-content against a standard of ADAMTS-4 digested and deglycosylated human cartilage A1D1 aggrecan. Samples from examinations A and B were analysed separately but directly following each other over a period of 4 months using the same batches of standard, high bind 96-well microtitre MSD plates, and antibodies. Data for SF ARGS at examination A has been previously published in a study using these samples 11 . Inter and intra assay coefficients of variations were as reported 11 .
Statistical analysis
We used the Shapiro-Wilk test to assess normal distribution of SF ARGS, Pearson's correlation (r) for normally distributed continuous variables and Spearman's rank order correlation (r S ) when categorical variables were included. For comparison of SF ARGS between examinations A and B we used a paired samples t test. For group comparison of SF ARGS in males and females we used analysis of covariance (ANCOVA) with or without adjustments for age, body mass index (BMI), and time between meniscectomy and examination A; for other group comparisons of means we used Student's t test. We used Pearson's Chi-square test for comparisons of frequencies between groups.
For analysis of longitudinal associations between SF ARGS and progression of ROA and KOOS we used univariate and multivariate logistic regression. For analysis of associations between SF ARGS at either examination and progression of ROA and KOOS, odds ratios (ORs) were calculated without adjustments (crude) or with adjustments for age, gender, BMI, and time between examinations A and B, with the reported ORs reflecting an incremental increase of 1 pmol ARGS/ml. To study the association between the change in levels of SF ARGS between examinations and progression of ROA and KOOS, we created a dichotomous SF ARGS variable; increase or decrease. In addition to the adjustments above, in the final model we also adjusted for SF ARGS levels at examination A 11 . We considered P below 0.05 to be significant. All tests were two-tailed and performed using SPSS (Chicago, IL, USA) for Windows, version 17.0.0.
Results
Subject characteristics
Analyses were made on all subjects with SF available from examination A (Study cohort n ¼ 141), and on the subset of subjects with SF available also from examination B (Subset n ¼ 74) (Fig. 2) . Characteristics of Study cohort n ¼ 141 have been described 11 ; characteristics of Subset n ¼ 74 are presented in Table I . Selfreported patient-relevant outcomes (KOOS) for all 141 subjects and for the Subset n ¼ 74 are presented in Table II . No statistically significant differences were noted between the larger Study cohort and the Subset regarding patient characteristics, radiographic status and KOOS scores at either examination, or change in radiographic status and KOOS scores from examination A to examination B, nor between the 67 subjects lacking SF at examination B and the Subset n ¼ 74 (not shown).
SF ARGS-aggrecan: gender differences and correlations
We found SF ARGS at examinations A and B to be normally distributed (P ¼ 0.65 and 0.85, respectively). In this sample and time frame (range 15e22 years) we found no significant correlation between SF ARGS and time from meniscectomy (P ¼ 0.36). In the Subset n ¼ 74 with SF samples available from both examinations, SF ARGS concentrations showed a correlation between examinations [ Fig. 3(A) ], and the mean concentrations did not differ significantly between examinations (6.66 and 7.06 pmol ARGS/ml at examinations A and B, respectively; P ¼ 0.21; Table I ). In longitudinal change in SF ARGS from examination A to examination B, those with higher levels at examination A tended to decrease, and those with lower levels at examination A tended to increase [ Fig. 3(B) ].
As reported, there was a significantly higher concentration of SF ARGS at examination A in men compared with women in the whole Study cohort n ¼ 141 11 . At examination B (in Subset n ¼ 74), no statistically significant gender differences in SF ARGS were observed, with concentrations in men and women being 7.14 (0.12e14.71) and 6.69 (2.63e10.05) pmol ARGS/ml, respectively. BMI was higher in men at both examinations (P < 0.001 examination A, P ¼ 0.002 examination B) with mean (range) values for men and women being 26.6 (22.2e41.0) kg/m 2 and 22.7 (17.9e27.3) kg/m 2 at examination A, and 28.1 (23.0e40.4) kg/m 2 and 24.4 (16.9e31.5) kg/m 2 at examination B. No correlation was, however, observed between SF ARGS and BMI at either examination (not shown). We found no correlation between SF ARGS and individual or summed scores of radiographic features of OA or patientrelevant outcomes in the KOOS instrument at examination A (n ¼ 141) or at examination B (n ¼ 74) (data not shown).
SF ARGS-aggrecan and its association with progression of radiographic features of OA Examination A levels of SF ARGS
As reported 11 , a weak inverse association between SF ARGS concentration at examination A and loss of joint space from examination A to examination B was present in the larger Study cohort n ¼ 141 (Table III ). Associations in Subset n ¼ 74 were essentially the same, with ORs 0.90, 0.95, and 0.87 for loss of joint space, osteophyte progression and progression of ROA, respectively, Values are mean (SD). There were no statistically significant differences in KOOS dimensions between the Study cohort and the Subset.
although the smaller sample size increased the confidence intervals (not shown) and the cross-sectional association with loss of joint space was no longer significant.
Examination B levels of SF ARGS
The examination B levels of SF ARGS in Subset n ¼ 74 were inversely associated with loss of joint space from examination A to examination B (odds ratio (OR) 0.78; Table III) , and with progression of ROA from examination A to examination B (OR 0.73; Table III) , where higher SF ARGS levels decreased the risk of radiographic progression. Although the logistic regression analysis showed ORs below one also for SF ARGS at examination B and osteophyte progression up to examination B, no significant association was seen (Table III) . Radiographic outcomes (loss of joint space, osteophyte progression, and ROA progression) are based on progression from examination A to examination B of the scores of JSN, osteophytes, and either JSN or osteophytes or both, scored according to the OARSI atlas 16 . Worsening of patient-relevant outcomes was assessed by KOOS 12, 13 ; progression was defined as a worsening in the respective score by 10 units or more 18 
Changing levels of SF ARGS from examination A to examination B
In subjects who decreased in SF ARGS-aggrecan from examination A to examination B, the likelihood for loss of joint space between examinations was increased 3-fold compared to those increasing in SF ARGS (crude OR 2.80; Table III ). Including adjustments for age, gender, BMI and time between visits did not essentially alter this estimate of risk, but including adjustments also for SF ARGS concentration at examination A increased the point estimate further (adjusted OR 5.72; Table III) .
With ORs around one, decreasing SF ARGS did not show an association with osteophyte progression (Table III) .
In subjects with decreasing SF ARGS, the risk of progression of the combination of loss of joint space and osteophytes (ROA progression) was essentially the same as the risk for loss of joint space alone (Table III) .
SF ARGS-aggrecan and its association with KOOS
No significant associations were seen between SF ARGS levels at either examination and progression of any of the five KOOS dimensions (Table III) .
In subjects who decreased in SF ARGS-aggrecan from examination A to examination B, the likelihood for KOOS pain worsening between examinations was increased 3.7-fold compared to those increasing in SF ARGS (OR 3.66, P ¼ 0.048; Table III ). None of the other four KOOS dimensions associated with decreasing SF ARGS (Table III) .
Discussion
We showed for this study cohort that 18 years after meniscectomy SF ARGS concentrations were inversely associated with future loss of joint space in the following 4 e10 years, where low levels increased the risk of progression and higher levels decreased the risk 11 . In the present study we corroborate our earlier findings by showing the same inverse association between SF ARGS concentrations, but now between ARGS-aggrecan levels at the second examination 4e10 years later and loss of joint space prior to that examination. Importantly, we here extend these findings to show that, regardless of SF ARGS level at examination A, a decrease in SF ARGS over the following 4e10 years was associated with a six-fold increased likelihood of loss of joint space over the same times period. This estimated risk was not substantially altered by the addition of osteophyte progression to loss of joint space (a combination here termed ROA progression), which is in agreement with our findings that SF ARGS seems to be unrelated to osteophyte progression. Within the range of levels seen in these subjects, having low levels of SF ARGS, or having decreasing levels of SF ARGS over time, thus appears to be associated with a higher risk of loss of joint space. For this patient cohort SF ARGS thus qualifies as marker prognostic of disease in the Burden of disease, Investigative, Prognostic of disease, Efficacy of intervention, Diagnostic of disease, and Safety of intervention (BIPEDS) classification of OA biomarkers 3 .
These results may seem inconsistent with multiple previous reports placing aggrecan degradation as central in OA pathology, and aggrecanase activity as detrimental to cartilage integrity. Ablation of aggrecanase activity has been shown to be protective of OA development in mouse models of OA 23, 24 . Since the first evidence emerging of an aggrecanase being involved in human joint pathology 25, 26 , aggrecanase activity giving rise to the release of ARGS-aggrecan from the cartilage has been shown to be increased above normal under inflammatory conditions in vitro 27, 28 , in inflammation in vivo 9,10,29 , following a knee trauma 9, 10, 29, 30 , as well as in subjects with knee OA 9, 10, 29 . The SF concentrations of ARGS-aggrecan in the acute phases of injury or inflammation in vivo were in some cases more than 100 times increased compared to SF of knee healthy subjects 9 . The levels of SF ARGS and change in those levels between examinations described here are much lower, and fall within the range of levels found in unoperated matched reference subjects without meniscus injury 11 . With SF levels of the CS846 epitope, (proposed to be present only on newly synthesised aggrecan 31 ) being elevated two-to three-fold up to 20 years following a knee injury compared to uninjured 32 (suggesting an increased de novo aggrecan synthesis) not only aggrecan catabolism but also aggrecan anabolism appears to be affected by knee trauma and arthritis. The relatively small fluctuations in the concentrations of SF ARGS seen in these patients long after meniscectomy are thus likely to be affected by variations in both aggrecan synthesis and aggrecanase activity. In contrast, the extreme elevation in SF ARGS seen in the acute phases of joint injury or inflammation may be due to larger variations in aggrecanase activity where the effect of variations of aggrecan synthesis are likely to be overshadowed 9, 10, 29 . In the subjects studied here, on average 18 years after meniscectomy, we hypothesise that the lower risk for loss of joint space seen in subjects that have higher or over time increasing levels of SF ARGS, is a reflection of a tissue repair response involving increased synthesis of aggrecan in combination with aggrecanase activity. Increased de novo synthesis of aggrecan that is in part successfully incorporated in the tissue and in part degraded by aggrecanase activity resulting in a net beneficial incorporation, would best explain a lower risk for ROA progression and a simultaneous release of ARGS-aggrecan.
It appears as if SF ARGS within the low levels found in these subjects can be interpreted as an anabolic marker (through its inverse association with loss of joint space). In acute stages of knee injury and in inflammation the marker is elevated many-fold above normal 9,10,29 , and appears as a marker of catabolism. This apparent duality in the interpretation of SF ARGS as a marker, suggests that a combination of markers of synthesis and degradation is needed for a better understanding of the processes underlying the release of proteolytic fragments into SF.
To the best of our knowledge, this study is the first to show that aggrecan ARGS-fragments in SF are associated with pain in human OA. The correlation between radiographic features of OA and pain is poor 16, 33 . Others have presented evidence suggesting that aggrecan fragments may be involved in pain pathogenesis through their ability to modulate neurite growth 34, 35 . Furthermore, in a mouse model of OA, ADAMTS-5 deficient mice do not develop mechanical allodynia associated with OA 36 . It is therefore possible that the association between changing SF levels of ARGS-aggrecan and pain seen in this study may be caused by the aggrecan fragments having a direct involvement in pain development, as well as indirectly through loss of joint space (i.e., loss of joint cartilage and meniscus), and development of bone marrow lesions 37, 38 .
When studying the association between changing levels of SF ARGS and progression of our outcomes, we have (in addition to the adjustments for age, gender, BMI and time between examinations) included SF ARGS levels at examination A in the final model. We did this knowing that SF ARGS levels at examination A showed an inverse association with loss of joint space 11 : a decrease from initially low levels of SF ARGS would have a different starting point than a decrease from higher levels. To study the effect of the change itself, we therefore included SF ARGS at examination A in the final model. For transparency, we show ORs from the final model, as well as for the crude model and the model adjusted for only age, gender, BMI, and time between examinations.
This study has several limitations. Only about half of the subjects included in the study had SF available at both examinations. The loss of power due to the reduced number of subjects is the reason why we have not made the regression analysis stratified for absence and presence of ROA in the subset, as we previously did for the larger Study cohort n ¼ 141 11 . Furthermore, we cannot exclude that variable clearance rates of matrix molecules from the joint cavity might influence the associations noted here, but with marker concentrations measured long after trauma a steady state between markers released into the SF and markers cleared from the SF has likely occurred 39 .
In conclusion we found that in middle-aged subjects with a meniscectomy 18 years earlier, SF ARGS levels were predictive of disease progression, where decreasing levels of SF ARGS over the next 4e10 years were associated with an increased risk for loss of joint space and worsening of knee pain over the same time period.
